Sweden's Bactiguard Q4 revenue beats estimates

Reuters

02/05

Sweden's Bactiguard Q4 revenue beats estimates

Overview

Swedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjusted
Q4 operating profit improved to SEK 13.0 mln from SEK -3.2 mln
Company's Q4 EBITDA rose to SEK 24.7 mln from SEK 8.4 mln

Outlook

Bactiguard aims for double-digit revenue growth in Wound Management portfolio in 2026
Company plans to secure additional partnerships and support existing partners in 2026
Bactiguard to enhance operational efficiency to support growth and profitability

Result Drivers

ZIMMER BIOMET AGREEMENT - Updated agreement with Zimmer Biomet boosted Q4 revenue and profitability in license business
HYDROCYN AQUA GROWTH - Double-digit growth in Hydrocyn aqua product line offset declines in other areas
CURRENCY IMPACT - Total revenue negatively impacted by US dollar exchange rates and discontinued products

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	SEK 65.60 mln	SEK 51 mln (1 Analyst)
Q4 Adjusted EPS		SEK 0.36
Q4 Net Income		SEK 12.50 mln
Q4 EBITDA		SEK 24.70 mln
Q4 Operating Cash Flow		SEK 11.70 mln
Q4 Operating Profit		SEK 13 mln

Analyst Coverage

The one available analyst rating on the shares is "hold"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Bactiguard Holding AB is SEK26.25, about 76.8% above its February 4 closing price of SEK14.85

Press Release: ID:nWkrbhS21N

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2609771340"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609771340\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609771340?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 14:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609771340","market":"fut","top_or_hot":-1,"title":"Sweden's Bactiguard Q4 revenue beats estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's Bactiguard Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Swedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjusted</p></li><li><p>Q4 operating profit improved to SEK 13.0 mln from SEK -3.2 mln</p></li><li><p>Company's Q4 EBITDA rose to SEK 24.7 mln from SEK 8.4 mln</p></li></ul><p><span>Outlook</span></p><ul><li><p>Bactiguard aims for double-digit revenue growth in Wound Management portfolio in 2026</p></li><li><p>Company plans to secure additional partnerships and support existing partners in 2026</p></li><li><p>Bactiguard to enhance operational efficiency to support growth and profitability</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ZIMMER BIOMET AGREEMENT - Updated agreement with Zimmer Biomet boosted Q4 revenue and profitability in license business</p></li><li><p>HYDROCYN AQUA GROWTH - Double-digit growth in Hydrocyn aqua product line offset declines in other areas</p></li><li><p>CURRENCY IMPACT - Total revenue negatively impacted by US dollar exchange rates and discontinued products</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>SEK 65.60 mln</p></td><td><p>SEK 51 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td></td><td><p>SEK 0.36</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>SEK 12.50 mln</p></td><td></td></tr><tr><td><p>Q4 EBITDA</p></td><td></td><td><p>SEK 24.70 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Cash Flow</p></td><td></td><td><p>SEK 11.70 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Profit</p></td><td></td><td><p>SEK 13 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Bactiguard Holding AB is SEK26.25, about 76.8% above its February 4 closing price of SEK14.85</p></li></ul><p>Press Release: <span>ID:nWkrbhS21N</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sweden's Bactiguard Q4 revenue beats estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSweden's Bactiguard Q4 revenue beats estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 14:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's Bactiguard Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Swedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjusted</p></li><li><p>Q4 operating profit improved to SEK 13.0 mln from SEK -3.2 mln</p></li><li><p>Company's Q4 EBITDA rose to SEK 24.7 mln from SEK 8.4 mln</p></li></ul><p><span>Outlook</span></p><ul><li><p>Bactiguard aims for double-digit revenue growth in Wound Management portfolio in 2026</p></li><li><p>Company plans to secure additional partnerships and support existing partners in 2026</p></li><li><p>Bactiguard to enhance operational efficiency to support growth and profitability</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ZIMMER BIOMET AGREEMENT - Updated agreement with Zimmer Biomet boosted Q4 revenue and profitability in license business</p></li><li><p>HYDROCYN AQUA GROWTH - Double-digit growth in Hydrocyn aqua product line offset declines in other areas</p></li><li><p>CURRENCY IMPACT - Total revenue negatively impacted by US dollar exchange rates and discontinued products</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>SEK 65.60 mln</p></td><td><p>SEK 51 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td></td><td><p>SEK 0.36</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>SEK 12.50 mln</p></td><td></td></tr><tr><td><p>Q4 EBITDA</p></td><td></td><td><p>SEK 24.70 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Cash Flow</p></td><td></td><td><p>SEK 11.70 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Profit</p></td><td></td><td><p>SEK 13 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Bactiguard Holding AB is SEK26.25, about 76.8% above its February 4 closing price of SEK14.85</p></li></ul><p>Press Release: <span>ID:nWkrbhS21N</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1267930573.SGD","symbol_name":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL1N3Z1083:1","article_id":"2609771340","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609771340","pubTimestamp":1770271983,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sweden's Bactiguard Q4 revenue beats estimatesOverviewSwedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjustedQ4 operating profit improved to SEK 13.0 mln from SEK ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","BK4566":"资本集团","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","ZBH":"齐默巴奥米特控股","BK4082":"医疗保健设备","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","BK4504":"桥水持仓","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4588":"碎股","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4585":"ETF&股票定投概念","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD"},"translate_title":"瑞典Bactiguard第四季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBH":0.9},"content_text":"Sweden's Bactiguard Q4 revenue beats estimatesOverviewSwedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjustedQ4 operating profit improved to SEK 13.0 mln from SEK -3.2 mlnCompany's Q4 EBITDA rose to SEK 24.7 mln from SEK 8.4 mlnOutlookBactiguard aims for double-digit revenue growth in Wound Management portfolio in 2026Company plans to secure additional partnerships and support existing partners in 2026Bactiguard to enhance operational efficiency to support growth and profitabilityResult DriversZIMMER BIOMET AGREEMENT - Updated agreement with Zimmer Biomet boosted Q4 revenue and profitability in license businessHYDROCYN AQUA GROWTH - Double-digit growth in Hydrocyn aqua product line offset declines in other areasCURRENCY IMPACT - Total revenue negatively impacted by US dollar exchange rates and discontinued productsKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeatSEK 65.60 mlnSEK 51 mln (1 Analyst)Q4 Adjusted EPSSEK 0.36Q4 Net IncomeSEK 12.50 mlnQ4 EBITDASEK 24.70 mlnQ4 Operating Cash FlowSEK 11.70 mlnQ4 Operating ProfitSEK 13 mlnAnalyst CoverageThe one available analyst rating on the shares is \"hold\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy.\"Wall Street's median 12-month price target for Bactiguard Holding AB is SEK26.25, about 76.8% above its February 4 closing price of SEK14.85Press Release: ID:nWkrbhS21NFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}